Research IP brings you the RIPPL Roundup each month to provide an early market snapshot for New Zealand and Australian financial advisers.
Magellan has announced that Hamish Douglass will take a medical leave of absence. With the recent departure of the CEO, relative underperformance and losing their largest mandate, is this the beginning of the end?
The Magellan Global Fund has retained its "5 IP" rating from Research IP, with a score of 4.40/5.
The Magellan Infrastructure Fund has been upgraded to a "5 IP" rating from Research IP, with a score of 4.27/5.
The Perpetual Global Share Fund has been issued a "4 IP" rating by Research IP, with a score of 3.80/5.
The Fairlight Global Small and Mid Cap Fund has been issued a "4 IP" rating by Research IP, with a score of 3.80/5.
The Harbour T. Rowe Price Global Equity Growth Fund has been issued a "4 IP" rating by Research IP, with a score of 4.20/5.
The Harbour Long Short Fund has been issued a "4 IP" rating by Research IP, with a score of 3.87/5.
The QuayStreet New Zealand Equity Fund has been issued a "4 IP" rating by Research IP, with a score of 3.78/5.
The Harbour Australasian Equity Focus Fund has been issued a "5 IP" rating by Research IP, with a score of 4.27/5.